IN8bio, Inc.
INAB
$1.80
-$0.11-5.76%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -9.32% | -31.81% | -23.18% | -28.17% | -14.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.14% | -34.33% | -40.14% | -34.53% | -21.49% |
| Operating Income | 19.14% | 34.33% | 40.14% | 34.53% | 21.49% |
| Income Before Tax | 19.77% | 45.61% | 40.97% | 35.18% | 18.93% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 19.77% | 45.61% | 40.97% | 35.18% | 18.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.77% | 45.61% | 40.97% | 35.18% | 18.93% |
| EBIT | 19.14% | 34.33% | 40.14% | 34.53% | 21.49% |
| EBITDA | 18.64% | 35.32% | 43.60% | 37.04% | 23.23% |
| EPS Basic | 70.69% | 81.09% | 77.54% | 66.39% | 63.93% |
| Normalized Basic EPS | 70.69% | 77.74% | 77.54% | 66.39% | 63.93% |
| EPS Diluted | 70.69% | 81.09% | 77.54% | 66.39% | 63.93% |
| Normalized Diluted EPS | 70.69% | 77.74% | 77.54% | 66.39% | 63.93% |
| Average Basic Shares Outstanding | 173.69% | 187.67% | 162.87% | 92.85% | 124.75% |
| Average Diluted Shares Outstanding | 173.69% | 187.67% | 162.87% | 92.85% | 124.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |